Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trials
4 recruiting trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Early Phase 1 is the largest group at 67% (2 studies); the largest phase groups are Early Phase 1: 2, Phase 1 / Phase 2: 1.
Research is led by Tongji Hospital (2), Tianjin Huanhu Hospital (1), Tianjin Medical University General Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is CT103A cells (biological, 1 trial), followed by Cyclophosphamide and fludarabine, UCAR T-cell.
Track Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous...
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and...
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA）...
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the...
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen...
Biomarkers in Autoimmune Disease of Nervous System
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.